Novel Classification of Acromegaly in Accordance with Immunohistochemical Subtypes: Is There Really a Clinical Relevance?

Abstract

According to the recent studies, immunohistochemical subtypes of growth hormone (GH) secreting adenomas have been considered as a predictive factor in determining the clinical outcomes including biochemical, radiologic, and endocrine remission. In a 20 year-of time period, acromegaly patients who were treated and followed at the Endocrinology Department of our University Hospital were screened for the study. Of total 98 patients, 65 patients who had been operated by transsphenoidal surgery and having postoperative specimens were included. Postoperative specimens of the surgery of the patients were classified into 3 groups based on the histochemical characteristics (densely, sparsely, and mixed). Parasellar extensions of pituitary tumors were classified into the five grades according to Knosp classification. The patients were investigated and evaluated for postoperative clinical progress, remission rates, comorbidities regarding with the histopathological patterns. Of total 65 patients, 31 were classified as densely granulated (group 1), 32 were classified as sparsely granulated (group 2), and 2 patients were assessed as mixed granulated (group 3). There was no difference between groups for age and gender. Pre-treatment of adenoma size in all groups was correlated with each other and the frequency of macroadenoma (1 vs. 2, 77.4 vs. 84.3%) was higher in two groups. Although mean initial GH levels in group 1 was higher than the other groups (p=0.03), IGF1 levels (age and gender matched) were similar in each group. Adenomas in all groups demonstrated noninvasive radiological characteristics (Knosp grade 0–1–2). Ki-67 proliferation index of both groups (64.5 vs. 50%) was predominantly 1%. With a similar follow-up period, the endocrine remission rates (GH<1 μg/l) in groups were 64 vs. 69%, respectively. In conclusion, classification according to immunohistochemical subtypes of growth hormone secreting adenomas may not be a qualified parameter to evaluate patients with patterns of aggressiveness, clinical outcomes, or treatment response.

Key words

densely granulated somatotroph adenoma - sparsely granulated adenoma - Ki 67 index - Knosp grade

Publication History

Received: 07 July 2021

Accepted after revision: 24 October 2021

Article published online:
29 November 2021

• References

• 1 Melmed S. Medical progress: Acromegaly. N Eng J Med 2006; 14: 2558-2573
• 2 Melmed S, Colao A, Barkan A. et al. Guidelines for acromegaly management: An update. J Clin Endocrinol Metab 2009; 94: 1509-1517
• 3 Obari A, Sano T, Ohyama K. et al. Clinicopathological features of growth hormone-producing pituitary adenomas: Difference among various types defined by cytokeratin distribution pattern including a transitional form. Endocr Pathol 2008; 19: 82-91
• 4 Yamada S, Aiba T, Sano T. et al. Growth hormone-producing pituitary adenomas: Correlations between clinical characteristics and morphology. Neurosurgery 1993; 33: 20-27
• 5 Bakhtiar Y, Hirano H, Arita K. et al. Relationship between cytokeratin staining patterns and clinico-pathological features in somatotropinomae. Eur J Endocrinol 2010; 163: 531-539
• 6 Mayr B, Buslei R, Theodoropoulou M. et al. Molecular and functional properties of densely and sparsely granulated GH-producing pituitary adenomas. Eur J Endocrinol 2013; 169: 391-400
• 7 Dworakowska D, Grossman AB. The pathophysiology of pituitary adenomas. Best Pract Res Clin Endocrinol Metab 2009; 23: 525-541
• 8 Lloyd RV, Gikas PW, Chandler WF. Prolactin and growth hormone-producing pituitary adenomas. An immunohistochemical and ultrastructural study. Am J Surg Pathol 1983; 7: 251-260
• 9 Mori R, Inoshita N, Takahashi-Fujigasaki J. et al. Clinicopathological features of growth hormone-producing pituitary adenomas in 242 acromegaly patients: Classification according to hormone production and cytokeratin distribution. ISRN Endocrinol 2013; 723432
• 10 Neumann PE, Goldman JE, Horoupian DS. et al. Fibrous bodies in growth hormone-secreting adenomas contain cytokeratin filaments. Arch Pathol Lab Med 1985; 109: 505-508
• 11 Mazal PR, Czech T, Sedivy R. et al. Prognostic relevance of intracytoplasmic cytokeratin pattern, hormone expression profile, and cell proliferation in pituitary adenomas of akromegalic patients. Clin Neuropathol 2001; 20: 163-171
• 12 Chatzellis E, Alexandraki KI, Androulakis K. Aggressive pituitary tumors. Neuroendocrinology 2015; 101: 87-104
• 13 Kato M, Inoshita N, Sugiyama T. et al. Differential expression of genes related to drug responsiveness between sparsely and densely granulated somatotroph adenomas. Endocr J 2012; 59: 221-228
• 14 Trouillas J, Roy P, Sturm N. et al. A new prognostic clinicopathological classification of pituitary adenomas: A multicentric case-control study of 410 patients with 8 years post-operative follow-up. Acta Neuropathol 2013; 126: 123-135
• 15 Bhayana S, Booth GL, Asa SL. et al. The implication of somatotroph adenoma phenotype to Somatostatin analog responsiveness in acromegaly. J Clin Endocrinol Metab 2005; 90: 6290-6295
• 16 Fougner SL, Casar-Borota O, Heck A. et al. Adenoma granulation pattern correlates with clinical variables and effect of somatostatin analogue treatment in a large series of patients with acromegaly. Clin Endocrinol 2012; 76: 96-102
• 17 Yuen KCJ. Medical therapy for acromegaly: Towards the practice of a personalised medicine approach. Endocr Pract 2019; 25: 396-398
• 18 Shanik MH. Limitations of current approaches for the treatment of acromegaly. Endocr Pract 2016; 22: 210-219
• 19 Ramos D, Carmichael J, Cooper O. et al. A structural and functional acromegaly classification. J Clin Endocrinol Metab 2015; 100: 122-131
• 20 Katznelson L, Laws ER, Melmed S. et al. Acromegaly: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2014; 99: 3933-3951
• 21 Knosp E, Steiner E, Kitz K, Matula C. Pituitary adenomas with invasion of the cavernous sinus space: A magnetic resonance imaging classification compared with surgical findings. Neurosurgery 1993; 33: 610-617
• 22 Kiseljak-Vassiliades K, Carlson NE, Borges MT. et al. Growth hormone tumor histological subtypes predict response to surgical and medical therapy. Endocrine 2015; 49: 231-241
• 23 Shimon I, Yan X, Taylor JE, Weiss MH. et al. Somatostatin receptor (SSTR) subtype-selective analogues differentially suppress in vitro growth hormone and prolactin in human pituitary adenomas. Novel potential therapy for functional pituitary tumors. J Clin Invest 1997; 100: 2386-2392
• 24 Lopes MB. Growth hormone-secreting adenomas: pathology and cell biology. Neurosurg Focus 2010; 29: E2
• 25 Osamura RY, Kajiya H, Takei M. et al. Pathology of the human pituitary adenomas. Histochem Cell Biol 2008; 130: 495-507
• 26 Bando H, Sano T, Ohshima T. et al. Differences in pathological findings and growth hormone responses in patients with growth hormone-producing pituitary adenoma. Endocrinol Jpn 1992; 39: 355-363
• 27 Mori R, Inoshita N, Takahashi-Fujigasaki J. et al. Clinicopathological features of growth hormone-producing pituitary adenomas in 242 acromegaly patients: classification according to hormone production and cytokeratin distribution. ISRN Endocrinol 2013; 723432
• 28 Fougner SL, Casar-Borota O, Heck A. et al. Adenoma granulation pattern correlates with clinical variables and effect of somatostatin analogue treatment in a large series of patients with acromegaly. Clin Endocrinol (Oxf) 2012; 76: 96-102
• 29 Mercado M, Espinosa de los Monteros AL, Sosa E. et al. Clinical-biochemical correlations in acromegaly at diagnosis and the real prevalence of biochemically discordant disease. Horm Res 2004; 62: 293-299
• 30 Cottier JP, Destrieux C, Brunereau L. et al. Cavernous sinus invasion by pituitary adenoma: MR imaging. Radiology 2000; 215: 463-469
• 31 Donegan DM, Iñiguez-Ariza N, Sharma A. et al. Necessity of multimodal treatment of acromegaly and outcomes. Endocr Pract 2018; 24: 668-676
• 32 Swanson A, Erickson D, Donegan D, Jenkins S. et al. Clinical, biological, radiological, and pathological comparison of sparsely and densely granulated somatotroph adenomas: A single center experience from a cohort of 131 patients with acromegaly. Pituitary 2021; 24: 192-206
• 33 Babu H, Ortega A, Nuno M. et al. Long-term endocrine outcomes following endoscopic endonasal transsphenoidal surgery for acromegaly and associated prognostic factors. Neurosurgery 2017; 81: 357-366
• 34 Nishioka H, Fukuhara N, Horiguchi K, Yamada S. Aggressive transsphenoidal resection of tumors invading the cavernous sinus in patients with acromegaly: Predictive factors, strategies, and outcomes. J Neurosurg 2014; 121: 505-510